QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
QQQ   354.90 (+0.07%)
AAPL   179.58 (-0.76%)
MSFT   335.94 (+0.16%)
META   271.39 (-0.45%)
GOOGL   126.01 (+1.07%)
AMZN   125.30 (+0.85%)
TSLA   217.61 (+1.70%)
NVDA   391.71 (-0.40%)
NIO   7.66 (+1.32%)
BABA   84.39 (+0.14%)
AMD   117.93 (+0.06%)
T   15.39 (+1.18%)
F   12.59 (+1.61%)
MU   67.77 (-2.02%)
CGC   0.78 (-4.86%)
GE   104.12 (-1.60%)
DIS   91.00 (+0.25%)
AMC   4.63 (+1.76%)
PFE   38.65 (+0.76%)
PYPL   64.51 (+0.86%)
NFLX   403.54 (+0.77%)
NASDAQ:MYMD

MyMD Pharmaceuticals (MYMD) Competitors

$1.66
-0.15 (-8.29%)
(As of 06/5/2023 ET)
Compare
Today's Range
$1.63
▼
$1.85
50-Day Range
$1.44
▼
$2.26
52-Week Range
$0.90
▼
$6.15
Volume
561,095 shs
Average Volume
471,061 shs
Market Capitalization
$65.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
ProfileChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

MYMD vs. NYMX, ICCC, TKNO, TRIB, ACHV, AWH, OCX, BMRA, FBIO, and MLSS

Should you be buying MyMD Pharmaceuticals stock or one of its competitors? The main competitors of MyMD Pharmaceuticals include Nymox Pharmaceutical (NYMX), ImmuCell (ICCC), Alpha Teknova (TKNO), Trinity Biotech (TRIB), Achieve Life Sciences (ACHV), Aspira Women's Health (AWH), OncoCyte (OCX), Biomerica (BMRA), Fortress Biotech (FBIO), and Milestone Scientific (MLSS). These companies are all part of the "medical" sector.

MyMD Pharmaceuticals vs.

Nymox Pharmaceutical (NASDAQ:NYMX) and MyMD Pharmaceuticals (NASDAQ:MYMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, earnings, valuation, profitability, risk, media sentiment, dividends and community ranking.

Nymox Pharmaceutical has a beta of 0.82, suggesting that its stock price is 18% less volatile than the S&P 500. Comparatively, MyMD Pharmaceuticals has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500.

In the previous week, Nymox Pharmaceutical had 1 more articles in the media than MyMD Pharmaceuticals. MarketBeat recorded 1 mentions for Nymox Pharmaceutical and 0 mentions for MyMD Pharmaceuticals. Nymox Pharmaceutical's average media sentiment score of 0.00 equaled MyMD Pharmaceuticals' average media sentiment score.

Company Overall Sentiment
Nymox Pharmaceutical Neutral
MyMD Pharmaceuticals Neutral

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nymox Pharmaceutical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
MyMD Pharmaceuticals
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

Nymox Pharmaceutical received 150 more outperform votes than MyMD Pharmaceuticals when rated by MarketBeat users.

CompanyUnderperformOutperform
Nymox PharmaceuticalOutperform Votes
150
51.72%
Underperform Votes
140
48.28%
MyMD PharmaceuticalsN/AN/A

MyMD Pharmaceuticals' return on equity of -81.66% beat Nymox Pharmaceutical's return on equity.

Company Net Margins Return on Equity Return on Assets
Nymox Pharmaceutical N/A -1,589.50% -117.25%
MyMD Pharmaceuticals N/A -81.66% -59.00%

Nymox Pharmaceutical is trading at a lower price-to-earnings ratio than MyMD Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nymox PharmaceuticalN/AN/A-$6.58 million-$0.04-10.20
MyMD PharmaceuticalsN/AN/A-$15.20 million-$0.36-4.66

0.8% of Nymox Pharmaceutical shares are owned by institutional investors. Comparatively, 9.6% of MyMD Pharmaceuticals shares are owned by institutional investors. 54.0% of Nymox Pharmaceutical shares are owned by insiders. Comparatively, 3.6% of MyMD Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

Nymox Pharmaceutical and MyMD Pharmaceuticals tied by winning 5 of the 10 factors compared between the two stocks.


New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding MYMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

MYMD vs. The Competition

Export to Excel
MetricMyMD PharmaceuticalsDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$66.18M$2.25B$4.48B$6.29B
Dividend YieldN/A0.79%6.01%6.50%
P/E Ratio-4.6626.9994.1611.90
Price / SalesN/A54.093,380.6486.56
Price / CashN/A37.6322.0823.57
Price / Book4.536.044.695.46
Net Income-$15.20M$27.00M$116.10M$192.22M
7 Day Performance-22.73%-1.06%4.71%3.07%
1 Month Performance-0.19%-0.31%4.19%5.05%
1 Year Performance-44.29%-13.11%14.09%1.25%

MyMD Pharmaceuticals Competitors List

Export to Excel
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NYMX
Nymox Pharmaceutical
0 of 5 stars		$0.45
+9.8%		N/A+11.4%$40.72MN/A-11.253Gap Down
ICCC
ImmuCell
0 of 5 stars		$5.06
-5.4%		N/A-36.3%$39.22M$18.57M-7.3360Positive News
Gap Down
TKNO
Alpha Teknova
2.4475 of 5 stars		$3.79
+14.2%		$9.33
+146.3%		-51.4%$106.95M$41.42M-2.11237News Coverage
Positive News
TRIB
Trinity Biotech
1.452 of 5 stars		$0.90
-2.2%		N/A-31.9%$34.30M$74.78M-0.70543Gap Down
ACHV
Achieve Life Sciences
2.044 of 5 stars		$6.24
-0.6%		$18.50
+196.5%		-1.6%$112.57MN/A-1.6616
AWH
Aspira Women's Health
1.7255 of 5 stars		$3.29
-6.0%		$30.00
+811.9%		-60.7%$27.41M$8.18M-0.25106
OCX
OncoCyte
2.291 of 5 stars		$0.22
+4.7%		$1.11
+400.9%		N/A$26.49M$960,000.000.00N/AAnalyst Report
BMRA
Biomerica
0 of 5 stars		$1.54
flat		N/A-66.1%$25.89M$18.87M-2.8566
FBIO
Fortress Biotech
1.9475 of 5 stars		$0.54
-1.8%		$5.50
+924.2%		-40.0%$72.13M$75.74M-0.54173Analyst Report
MLSS
Milestone Scientific
0 of 5 stars		$1.04
+1.0%		N/A+8.4%$72.80M$8.81M-9.45N/AHigh Trading Volume

Related Companies and Tools

Related Companies:
Top 10 Stock Comparisons
This page (NASDAQ:MYMD) was last updated on 6/5/2023 by MarketBeat.com Staff

My Account -